Literature DB >> 21411501

Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction.

Martin C Tammemagi1, Stephen C Lam, Annette M McWilliams, Don D Sin.   

Abstract

Lung cancer is the leading cause of cancer death worldwide. Accurate prediction of lung cancer risk is of value for individuals, clinicians, and researchers. The aims of this study were to characterize the associations between pulmonary function and sputum DNA image cytometry (SDIC) and lung cancer, and their contributions to risk prediction. During 1990 to 2007, 2,596 high-risk individuals were enrolled and followed prospectively for development of lung cancer (n = 139; median follow-up 7.7 years) in trials at the British Columbia Cancer Agency. At baseline, an epidemiologic questionnaire was administered, sputum was collected for aneuploidy measurement and spirometry was obtained. Multivariable logistic models were prepared including known lung cancer predictors (model 1), that additionally included percent-expected-forced expiratory volume in 1 second [forced expiratory volume in 1 second (FEV(1)%), model 2], and that additionally included SDIC (model 3). Prediction was assessed by evaluating discrimination (receiver operator characteristic area under the curve (ROC AUC)) and calibration. Net reclassification indices (NRI) were calculated with cutoff points for 8-year risks identifying low, intermediate, and high risk at 1.5% and 3%. Lung cancer risk increased with decline in FEV(1)%, but did so more for men than for women (interaction P < 0.001). SDIC demonstrated a dose-response with lung cancer (P = 0.022). The ROC AUCs for models 1, 2, and 3 were 0.718 (95% CI: 0.671-0.765), 0.767 (95% CI: 0.725-0.809), and 0.773 (95% CI: 0.732-0.815), respectively. Model 2 versus 1 had a NRI of 12.6% (P < 0.0001) and model 3 versus 2 had a NRI of 3.1% (P = 0.059). Spirometry and SDIC data substantially and minimally improved lung cancer prediction, respectively. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411501     DOI: 10.1158/1940-6207.CAPR-10-0183

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  21 in total

1.  Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort.

Authors:  Raewyn J Hopkins; Fenghai Duan; Caroline Chiles; Erin M Greco; Greg D Gamble; Denise Aberle; Robert P Young
Journal:  Ann Am Thorac Soc       Date:  2017-03

2.  Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.

Authors:  C Martin Tammemagi; Paul F Pinsky; Neil E Caporaso; Paul A Kvale; William G Hocking; Timothy R Church; Thomas L Riley; John Commins; Martin M Oken; Christine D Berg; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2011-05-23       Impact factor: 13.506

Review 3.  The state of molecular biomarkers for the early detection of lung cancer.

Authors:  Mohamed Hassanein; J Clay Callison; Carol Callaway-Lane; Melinda C Aldrich; Eric L Grogan; Pierre P Massion
Journal:  Cancer Prev Res (Phila)       Date:  2012-06-11

Review 4.  Chronic obstructive pulmonary disease (COPD) and lung cancer screening.

Authors:  Robert P Young; Raewyn J Hopkins
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 5.  Blood based biomarkers beyond genomics for lung cancer screening.

Authors:  Samir M Hanash; Edwin Justin Ostrin; Johannes F Fahrmann
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 6.  Lung cancer screening: review and performance comparison under different risk scenarios.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Eduardo L Franco
Journal:  Lung       Date:  2013-10-24       Impact factor: 2.584

7.  Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.

Authors:  Juan P de-Torres; David O Wilson; Pablo Sanchez-Salcedo; Joel L Weissfeld; Juan Berto; Arantzazu Campo; Ana B Alcaide; Marta García-Granero; Bartolome R Celli; Javier J Zulueta
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

8.  Selection criteria for lung-cancer screening.

Authors:  Martin C Tammemägi; Hormuzd A Katki; William G Hocking; Timothy R Church; Neil Caporaso; Paul A Kvale; Anil K Chaturvedi; Gerard A Silvestri; Tom L Riley; John Commins; Christine D Berg
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

9.  Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.

Authors:  Rafael Meza; Kevin ten Haaf; Chung Yin Kong; Ayca Erdogan; William C Black; Martin C Tammemagi; Sung Eun Choi; Jihyoun Jeon; Summer S Han; Vidit Munshi; Joost van Rosmalen; Paul Pinsky; Pamela M McMahon; Harry J de Koning; Eric J Feuer; William D Hazelton; Sylvia K Plevritis
Journal:  Cancer       Date:  2014-02-27       Impact factor: 6.860

10.  A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment.

Authors:  Katrina Steiling; Maarten van den Berge; Kahkeshan Hijazi; Roberta Florido; Joshua Campbell; Gang Liu; Ji Xiao; Xiaohui Zhang; Grant Duclos; Eduard Drizik; Huiqing Si; Catalina Perdomo; Charles Dumont; Harvey O Coxson; Yuriy O Alekseyev; Don Sin; Peter Pare; James C Hogg; Annette McWilliams; Pieter S Hiemstra; Peter J Sterk; Wim Timens; Jeffrey T Chang; Paola Sebastiani; George T O'Connor; Andrea H Bild; Dirkje S Postma; Stephen Lam; Avrum Spira; Marc E Lenburg
Journal:  Am J Respir Crit Care Med       Date:  2013-05-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.